Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Debjeet Sur has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Asis Bala

    Pharmacology and Drug Discovery Research Laboratory, Division of Life Sciences, Institute of Advanced Study in Science and Technology (IASST), Guwahati, India

    4 shared publications
  • Sanchari Bhattacharya

    Department of Pharmacy, Guru Nanak Institute of Pharmaceutical Science and Technology, 157/F, Nilgunj Road,Panihati, Kolkata, 700114, India

    3 shared publications
  • Chaitali Mondal

    TCG Life Science (Chembiotek) Pvt. Ltd, Kolkata, India

    2 shared publications
  • Himangshu Sekhar Maji

    Department of Pharmaceutical Technology, JIS University, Kolkata, India

    2 shared publications
  • Oishani Chatterjee

    Division of Pharmacology, Guru Nanak Institute of Pharmaceutical Science & Technology, Panihati, Kolkata, 700114, India

    2 shared publications
  • Pallab Kanti Haldar

    Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India

    2 shared publications

Latest Publications

  • Bromocriptine Attenuated Ulcerative Colitis and Colonic Inflammation by Inhibiting IL-1β, Likely through NF-κB Down-regulation: Integrated Network Pharmacology and in vivo Experimental Validation

    by Sarthak Saha, Sourav Mondal, Oishani Chatterjee, Piyali Devroy, Debjeet Sur, Asis Bala

    Introduction: Gastrointestinal dopamine (DA) plays a crucial role in maintaining gut homeostasis. In patients with ulcerative colitis (UC), a decrease in DA levels due to changes in the gut microbiome can activate immune cells in the colon's mucosal layer, leading to the secretion of various inflammatory mediators and ultimately causing damage to the colonic mucosa. In the present study, we initially analysed integrated network pharmacology and investigated the protective effect of bromocriptine (BRO), a dopamine D2 receptor (D2R) agonist, on acetic acid (AA)-induced UC in rats. Methods: Wistar rats were randomly divided into six groups (N=6/group). The intrarectal administration of AA induced UC. Treatment groups (III-IV) received three doses (2, 5, and 10 mg/kg) of BRO once daily for seven days. Group VI animals were administered mesalamine. On the eighth day, the animals were sacrificed to evaluate the lesion scores, ulcer indices, histopathological findings, nitric oxide (NO) levels, and myeloperoxidase (MPO). Finally, tissue levels of interleukin (IL-1β) and nuclear factor kappa B (NF-κB) were measured using ELISA. Results: BRO treatment effectively improved the disease severity index (DAI), colonic lesion score, and ulcer index in rats with AA-induced UC. Histopathological studies revealed that treatment with BRO limited mucosal damage and neutrophil extravasation in colonic tissue. Moreover, biochemical assessments of MPO and NO showed a significant decrease in the levels of both inflammatory mediators following treatment with BRO. Additionally, the results indicated a reduction in the expression of IL-1β and NF-κB in colonic tissue, further supporting the amelioration of colonic inflammation caused by BRO. Discussion: The present research demonstrated that BRO exerts a protective effect by influencing the expression of IL-1β and NF-κB in rats with AA-induced UC, thus restricting the activity of immune cells in the colonic mucosa. Conclusion: Findings of this research suggest that BRO may be a promising therapeutic agent for the management of UC.

  • Open Access

    Autophagy-mediated Kupffer cell polarization in liver cirrhosis reversal: Mechanistic insights and therapeutic strategies

    by Debjeet Sur, Gargi Banik

    Liver cirrhosis, an advanced end-stage liver disease characterized by extensive hepatic fibrosis, is a leading cause of mortality and morbidity worldwide. Despite its prevalence, there is no specific treatment to prevent fibrosis progression, with liver transplantation remaining the only definitive option for patients with advanced cirrhotic liver disease. The activation of hepatic stellate cells (HSCs) by proinflammatory M1-type Kupffer cells (KCs) is a key driver of fibrosis. Activated HSCs further exacerbate fibrosis by recruiting bone marrow-derived macrophages (BMDMs) through chemokine signaling, which induces alpha-smooth muscle actin (alpha-SMA) expression. Autophagy, a cellular process responsible for degrading damaged organelles and protein aggregates, is vital for maintaining liver physiology and metabolic balance. It also plays a significant role in the pathogenesis of fibrosis. Compounds that promote KC autophagy can polarize KCs toward an anti-inflammatory M2 phenotype, disrupting signaling pathways that activate HSCs and recruit BMDMs to injured liver tissue. This approach has been identified as a promising therapeutic strategy to combat liver fibrosis. This review highlights various strategies to activate KC autophagy and modulate KC polarization, offering insights into novel therapeutic targets for treating liver fibrosis and preventing cirrhosis progression.

  • mRNA-Based Cancer Vaccines: A Review of the Current Scenario and Future Prospects

    by Sanchari Bhattacharya, Nilufa Easmin, Atanu Panja, Aditi Nayak, Debjeet Sur

    Messenger RNA (mRNA) has gained increasing attention as a valuable tool to cure various human diseases, particularly malignant tumors. Such growing interest has been triggered largely by the phenomenal clinical success of mRNA vaccines developed using lipid nanoparticle (LNP) technology against COVID-19. mRNA may be used to produce cancer immunotherapies in numerous different ways, including cancer vaccines to induce or enhance immunity to tumor-specific antigens (TSAs) or tumor-associated antigens (TAAs). mRNA can also be used to adoptively transfer T-cells for the expression of antigen receptors, such as chimeric antigen receptors (CARs), therapeutic antibodies, and immunomodulatory proteins to re-engineer the tumor microenvironment. However, the therapeutic potential of mRNA-based cancer immunotherapy is not fully utilized due to a few limitations, such as mRNA instability, production of immunogenicity, and a lack of efficient in-vivo delivery methods. This review provides an overview of the current advancements and future directions of mRNA-based cancer therapies, including various delivery routes and therapeutic platforms. It addresses the mechanistic basis of mRNA cancer vaccines, non-replicating and self-amplifying mRNA, as well as their clinical development, personalized vaccines, and applications of mRNA for encoding antigen receptors, antibodies, and immunomodulatory proteins. Moreover, the review addresses nanoparticle-based platforms, such as lipid nanoparticles (LNPs), polymeric nanoparticles, and peptide-based nanoparticles, all used to improve the therapeutic effectiveness of mRNA-based drugs by improving their targeted delivery to tissues. This review aims to provide insights into the use of state-of-the-art mRNA-based cancer immunotherapy.


  • The TIM-3/Gal-9 Pathway: A Promising Therapeutic Target for Regulation of Immune Checkpoint in Rheumatoid Arthritis

    by Debjeet Sur, Riya Pramanik

    Rheumatoid arthritis (RA) is a chronic autoimmune ailment that is marked by persistent synovial joint inflammation, which causes joint destruction and other systemic consequences. The immune system is equipped with a wide range of effector mechanisms that are capable of inflicting severe harm on pathogens that invade it, as well as inflicting severe harm on the body itself. The immune system must carefully regulate itself to avoid such damage to host tissues and restore equilibrium following an inflammatory response. In the peripheral immune system, the immune cell responses are regulated by a balance of positive and negative signals that are sent to effector cells to adjust them to their environment. The identification of immunological checkpoints has opened up new avenues for studying and perhaps modifying immune responses in the context of RA pathogenesis. T-cell immunoglobulin and mucin domain-containing molecule 3 (TIM-3), a member of the TIM family, has emerged as a major regulator in immune checkpoint pathways, with several studies on its various functions in immunological homeostasis and autoimmune disorders. This review narrates the critical function of TIM-3 in the control of immunological checkpoints in rheumatoid arthritis also the potential role of TIM-3/GAL-9 signalling as a therapeutic target for the development of a new class of immunotherapeutic agents for the treatment of RA.


  • Beyond CTLA-4 and PD-1: Novel Insights into MAO-A as a Next Generation Immune Checkpoint Modulator for Cancer Immunotherapy

    by Prajna Maity, Debjeet Sur

    Immune checkpoint blockade (ICB) has fundamentally transformed cancer treatment by unlocking the potency of CD8+ T cells by targeting the suppression of the CTLA-4 and PD-1/PD-L1 pathways. Nevertheless, ICBs are associated with the risk of severe side effects and resistance in certain patients, driving the search for novel and safer immune checkpoint modulators. Monoamine Oxidase A (MAO-A) plays an unexpected role in the field of cancer. Recent research has unveiled its dual nature: in the brain, it breaks down neurotransmitters, impacting mood and behaviour, while in tumours, its role takes a more complex turn. The involvement of MAO-A in the tumour microenvironment is crucial, affecting oxidative stress, hypoxia, and immune cell behaviour. Specifically, the regulation of tumour-associated macrophages (TAMs) and their polarisation underscores their potential as targets for cancer immunotherapy. MAO-A inhibition reprograms TAMs, shifting them from an immunosuppressive to an immunostimulatory state, thereby enhancing the activity of tumour-infiltrating CD8+ T cells. Interestingly, the presence of MAO-A in CD8+ T cells suggests its potential as a target for novel ICB therapy. This review lays the groundwork for a deeper understanding of the therapeutic potential of MAO-A by examining the intricate landscape of its role in cancer immunology. We envision a future in which harnessing the power of CD8+ T cells through optimised MAO-A targeting might lead to safer and more effective cancer treatments, offering hope for countless patients.


  • The 3C (Cell Culture, Computer Simulation, Clinical Trial) Solution for Optimizing the 3R (Replace, Reduction, Refine) Framework during Preclinical Research Involving Laboratory Animals

    by Susmita Roy, Mehnaz Parveen, Asis Bala, Debjeet Sur

    Preclinical research has traditionally utilized laboratory animals to elucidate the safety, tolerability, pharmacokinetics, and pharmacodynamics of new chemical entities prior to human trials. The use of animal models has been pivotal in advancing scientific knowledge and medical breakthroughs, contributing significantly to our understanding of the complex biological processes and human diseases. However, many promising treatments that have demonstrated efficacy in animal studies have failed to translate to human subjects during clinical trials. Consequently, animal testing faces ethical concerns and criticism regarding its predictive reliability for human responses. This has led to the development of 3R principles (Replacement, Reduction, Refinement), introduced in 1959, advocating for alternative methods and improved animal welfare in research. Furthermore, regulatory frameworks and recent legislation, such as the 2022 FDA Modernisation Act, emphasize modern scientific alternatives to traditional animal testing. Emerging approaches, known as the 3Cs─cell culture, computer simulation, and phase 0 clinical trials─offer promising nonanimal solutions that could accelerate drug development and address ethical concerns, potentially rendering preclinical research more humane and efficient.


  • Pharmacotherapy of Psychological Disorders Using Psychedelic Drugs: A Treatise for Psychiatrists

    by Payal Ghosh, Debjeet Sur

    : Psychedelics are currently being examined once more as potential remedies for untreatable biological illnesses after decades of research problems. They are frequently regarded to be physically safe and do not frequently lead to dependency or addiction. The use of psychedelic substances in the treatment of mental illness and the adoption of the Substance Act of 1970 has classified psychedelic drugs as Schedule I. The major objective of this review is to highlight the prospective use of specific psychedelic medicines, such as psilocybin, LSD, MDMA, and ayahuasca, in the treatment of various psychiatric conditions, such as treatment-resistant depression, post-traumatic traumatic stress, end-of-life anxiety, and substance misuse disorders. As documented from both animal and human studies, in addition, there will be a study of the effectiveness and safety. The body of research suggests that psychedelics may one day offer revolutionary treatments for mental diseases, contrary to conventional therapy. However, given their distinctive histories and a high potential for abuse with widespread distribution, more care and effort must be given to protect their use as efficient medical treatments instead of drugs of abuse.


  • Immuno-metabolic reprogramming of T cell: a new frontier for pharmacotherapy of Rheumatoid arthritis

    by Sourav Mondal, Sarthak Saha, Debjeet Sur

    Rheumatoid arthritis (RA) is a persistent autoimmune condition characterized by ongoing inflammation primarily affecting the synovial joint. This inflammation typically arises from an increase in immune cells such as neutrophils, macrophages, and T cells (TC). TC is recognised as a major player in RA pathogenesis. The involvement of HLA-DRB1 and PTPN-2 among RA patients confirms the TC involvement in RA. Metabolism of TC is maintained by various other factors like cytokines, mitochondrial proteins & other metabolites. Different TC subtypes utilise different metabolic pathways like glycolysis, oxidative phosphorylation and fatty acid oxidation for their activation from naive TC (T0). Although all subsets of TC are not deleterious for synovium, some subsets of TC are involved in joint repair using their anti-inflammatory properties. Hence artificially reprogramming of TC subset by interfering with their metabolic status poised a hope in future to design new molecules against RA.


  • Pioglitazone attenuate level of myeloperoxidases and nitic oxide in psoriatic lesion: a proof-of-concept study in a imiquimod induced psoriasis model in rat

    by Oishani Chatterjee, Debjeet Sur

    Objectives: Psoriasis is a persistent autoimmune inflammatory condition that is primarily affecting the skin. Pioglitazone (PGZ), a peroxisome proliferator activated receptor gamma (PPARγ) agonist, has been reported to have anti-inflammatory effects. However, the role of PGZ in psoriatic disease remains unclear. In this study, we aimed to repurpose the use of the PGZ for the treatment of psoriasis. Methods: To investigate its efficacy, we employed an imiquimod (IMQ)-induced rat model. Wistar rats are randomly allocated to four different groups. Group, I served as a negative control, Group II IMQ control, Group III was treated with pioglitazone hydrogel and Group IV received standard drug betamethasone cream. PASI score was monitored on every alternative day and on day 7 animals were sacrificed and histopathology of skin was performed. Level of nitric oxide (NO) and myeloperoxidase (MPO) was also performed using established methods. Results: The results of the experiment revealed that treatment with PGZ significantly (p<0.05) reduced redness, scaling, and skin thickening, surpassing the effectiveness of standard drugs. Our result also indicates that PGZ significantly (p<0.05) inhibits the release of both MPO and NO from the psoriatic lesions. Conclusions: PGZ effectively reduces the severity of psoriasis possibly by inhibiting the accumulation of neutrophil at the psoriatic area which indirectly regulates the release of NO in the affected area. Our study showed we can repurpose the PGZ for the management of psoriasis.


  • Potential Oncotherapeutic Effects of Nutraceuticals against Hepatocellular Carcinoma: Recent Advancements

    by Arghadip Das, Supravat Das, Sanchari Bhattacharya, Debjeet Sur, Samrat Bose, Tilottama Mukherjee

    Background: Worldwide, Hepatocellular carcinoma (HCC) is a frequently diagnosed cancer, having significant variations in its epidemiology. It ranks as the sixth prevailing neoplasm and is considered the third leading cause of mortality due to cancer. It accounts for 90% of primary liver cancers. Till date, an effective prevention or treatment is absent except for liver resection, chemotherapy and a frequently applied drug -sorafenib. Recently, various plant products and nutraceuticals are found to be effective in the treatment of HCC. ‘Nutraceuticals’ is a term that brings into light the two giants of health sciences - nutrient and pharmaceutical. Nutraceuticals provide medical or health benefits and include prevention or treatment of a disease. These are generally ‘functional foods’, which are whole, or ‘fortified, enriched and enhanced’ in nutritional value to satisfy the required amount of essential nutrients and to confer health benefits. Objective: This study is based on the recent advancements achieved in the field of HCC treatment using a variety of emerging nutraceuticals that are effective, solely, or act as an adjuvant in its treatment. Nutraceuticals such as standardized extracts of ginger, fucoidan, curcumin, proanthocyanidins, epigallocatechin gallate, apigenin and other nutraceuticals are being studied extensively for their efficacy against HCC along with their proposed mechanism of action or potential targets for the treatment or prevention of HCC.